Novartis Investigative Site

Weiden 92637

0 studies enrolling now · 11 studies all time

What they study most

Acute Decompensated Heart Failure, Acute Heart Failure, Advanced Breast Cancer, Breast Cancer, Cardiovascular Disease and Lipoprotein(a), Chronic Myeloid Leukemia, Congestive Heart Failure, Gastrointestinal Stromal Tumor (GIST), Metastatic Hormone Refractory Prostate Cancer, Metastatic Renal Cell Carcinoma, Myelogenous Leukemia, Renal Cell Carcinoma

Studies at this site

• Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer — Completed
• Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer. — Completed
• Lipoprotein(a) in Patients With Cardiovascular Disease (CVD) — Completed
• Efficacy and Safety of Patupilone in Men (≥18 Years) With Metastatic Hormone Refractory Prostate Cancer — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma — Completed
• A Study of Nilotinib Versus Imatinib in GIST Patients — Completed
• Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma — Completed
• Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure — Completed
• Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) — Stopped early
• Expanded Access Program of AMN107 in Imatinib-resistant or Intolerant Adult Patients With Chronic Myeloid Leukemia — NO_LONGER_AVAILABLE